Virosart® HF: High Speed Virus Filtration for mAbs and Recombinant Proteins

Birte Kleindienst*, Peter Kosiol
Sartorius Stedim Biotech GmbH, August-Spindler-Strasse 11, 37079 Goettingen
*Correspondence
E-Mail: birte.kleindienst@sartorius.com

Abstract

The commercial manufacturing of therapeutic antibodies or recombinant proteins requires robust and reliable processes that are economical and deliver high yields, while generating a product that is effective and safe for human use. One factor posing a threat to the patient safety is the presence of viruses in the final product. A contamination of products derived from human or animal cells with viruses can have disastrous clinical consequences. Therefore, regulatory authorities stress the need to implement robust and orthogonal strategies for virus clearance in order to meet the requirements of a risk-based approach to virus clearance assessment.

Virus filtration has traditionally been accepted as a robust method for virus clearance. This document summarizes the performance of the Virosart® HF in its typical field of application such as throughput, optimization studies and virus clearance.

Keywords or phrases:
Virus filtration,
virus clearance,
mAb’s, MVM, PP7

Find out more: www.sartorius.com
Disclaimer

The evaluation of a virus filter is not confined to its capacity to retain viruses. Selection of a virus filter is influenced by numerous factors including, but not limited to, flow rate, total batch throughput, fluid compatibility, process fluid attributes, potential risk from virus passage, unit costs, validation costs and costs of ancillary equipment.

The ideal virus filter will retain all virus sizes and allow high protein transmission, while maintaining a high flow rate without significant virus breakthrough. The purpose of this document is to provide users of Virosart® HF with an overview of its product throughput and virus retention performance characteristics under different process and feed stream conditions. A variety of studies have been designed and performed that reflect typical feed stream conditions used from process development up to commercial manufacturing in the biopharmaceutical industry. In addition further experiments have been performed outside of the typical manufacturing processes to show the robustness of the Virosart® HF filter with respect to filter throughput and retention. The results presented in this guide provide an indication of filter performance under the specific conditions tested. Similar results are likely also under different operating conditions. However, this is not guaranteed and users are requested to confirm throughput and retention characteristics under their specific process and feed stream conditions. Our application specialists from Separation Technologies will gladly assist in your filtration trial work. If required please contact your local Sartorius Stedim Biotech representative to obtain further information on technical data, product integrity testing or general information concerning specific applications.
# Table of Contents

1. **Introduction**  
   1.1 Virus Filtration  
   1.2 Product Overview  
   1.3 Product Release  

2. **Throughput**  
   2.1 Filtration Basics  
   2.2 Filtration of mAbs  
   2.3 Consistent Filter Throughput  
   2.4 Protein Transmission  
   2.5 Scalability  
   2.6 Post-Flushing Volume  
   2.7 Hold-up Volume  

3. **Process Optimization**  
   3.1 Fouling Behavior of Virus Filters  
   3.2 Adsorptive Pre-Filtration with Virosart \textsuperscript{®} Max  
   3.3 Dilution  
   3.4 pH and Conductivity  
   3.5 Decision Tree for Virus Filter Throughput Optimization  

4. **Virus Clearance**  
   4.1 Introduction  
   4.2 Virus Retention  
   4.3 Robust Retention  
   4.4 Retention under Challenging Conditions  
   4.5 Simulation of Transportation Conditions  

5. **Integrity Test**  
   5.1 Definition  
   5.2 Reasons  
   5.3 Correlation of IT and PP7 Retention  

6. **Abbreviations**  

7. **References**  

8. **Acknowledgements**
1. Introduction

1.1 Virus Filtration
The commercial manufacturing of therapeutic antibodies or recombinant proteins requires robust and reliable processes that are economical and deliver high yields, while generating a product that is effective and safe for human use. One factor posing a threat to the patient safety is the presence of viruses in the final product. A contamination of products derived from human or animal cells with viruses can have disastrous clinical consequences. Therefore, regulatory authorities stress the need to implement robust and orthogonal strategies for virus clearance in order to meet the requirements of a risk-based approach to virus clearance assessment.

Virus filtration has traditionally been accepted as a robust method for virus clearance. The Virosart® HF virus filter family incorporates an effective and robust virus clearance technology for small non-enveloped viruses combining high flow rate, high virus retention and high product throughput.

The main application for Virosart® HF filters is the virus filtration of monoclonal antibodies (mAbs), antibody fragments (Fab) or small recombinant proteins (< 150 kDa). Virosart® HF is used towards the end of the purification process of biopharmaceutical products for the virus filtration. At this stage, the purity of the biopharmaceutical product is at its highest and so fouling of the virus filter by contaminants (DNA, HCP, aggregates and lipoproteins) will be low.

1.2 Product Overview

1.2.1 Membrane
The Virosart® HF virus filter features an asymmetric polyether sulfone (PES) hollow-fiber membrane with a nominal pore size of 20 nm. This membrane is characterized by a funnel-like pore-size gradient to achieve robust retention of small viruses such as paroviruses under challenging conditions without impeding the quantitative transmission of product molecules. Further, to reduce the adsorption of proteins, protein aggregates or other potentially fouling species, the membrane is surface modified with a hydrogel-forming, low binding polymer.

1.2.2 Filter Device
Scalable filters of different sizes were developed to provide appropriate size selection and flexibility from process development up to commercial processing.

<table>
<thead>
<tr>
<th>Lab Modules</th>
<th>Nominal Filtration area: 1.7 cm² &amp; 5.0 cm²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Typical filtration volume: &lt; 500 mL</td>
<td></td>
</tr>
<tr>
<td>To be used for:</td>
<td></td>
</tr>
<tr>
<td>• Scale-down work</td>
<td></td>
</tr>
<tr>
<td>• Flow &amp; capacity studies</td>
<td></td>
</tr>
<tr>
<td>• Optimization of pre-filter-final-filter ratios</td>
<td></td>
</tr>
<tr>
<td>• GLP spiking studies</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mid-Scale Modules</th>
<th>Nominal Filtration area: 200 cm² &amp; 0.2 m²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Typical filtration volume: 0.5 – 50 L</td>
<td></td>
</tr>
<tr>
<td>To be used for:</td>
<td></td>
</tr>
<tr>
<td>• Scale-up studies</td>
<td></td>
</tr>
<tr>
<td>• Clinical phases</td>
<td></td>
</tr>
<tr>
<td>• Small-scale production</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Process Modules</th>
<th>Nominal Filtration area: 0.8 m² &amp; 2.4 m²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Typical filtration volume: &gt; 50 L</td>
<td></td>
</tr>
<tr>
<td>To be used for:</td>
<td></td>
</tr>
<tr>
<td>• Large scale manufacturing</td>
<td></td>
</tr>
</tbody>
</table>

Figure 1: Virosart® HF device set-up
1.3 Product Release

Sartorius Stedim Biotech operates ISO 9001 and ISO 13485 certified Quality Management Systems to assure the consistent high quality of all membrane filters. All materials are selected carefully in accordance with current regulations, such as the FDA CFR’s, cGMP’s in-house guidelines and the specifications of our research and development department including the terms of delivery and acceptance of our purchasing department. Documentation begins with the inspection of the incoming raw materials including in-process materials, molded parts and sealing materials, etc. for manufacturing. Adherence to cGMP requirements (clean-room conditions, gowning and employee hygiene, etc.) which are monitored by documented in-process controls, ensures optimal quality control in standard operating procedures for production. In addition, all materials selected are highly unlikely to present a risk of TSE/ BSE transmission. Our philosophy at Sartorius Stedim Biotech is to validate and test the membranes of our products extensively in order to assure the quality of all our filtration products. Below, an extract of membrane and final device release testing procedures for the Virosart® HF filter family is shown.

1.3.1 Membrane Release Testing

Extensive testing takes place during the whole membrane casting and release process. Membrane release testing includes, but is not limited to, the following tests:

**Water and Buffer Flow Rate Test**
Water | buffer permeability is an important parameter, as product throughput correlates to permeability. By testing the water and buffer permeability of the membrane, we can ensure reproducible, consistent and fast processing in the biopharmaceutical manufacturing process. Based on a defined sampling plan, the water and buffer flow rate at 2.0 bar | 30 psi operating pressure of each Virosart® HF membrane lot are tested. A 20 mM KPI buffer pH 7.2 is used as buffer.

**Bacteriophage Challenge Testing**
Retention of Pseudomonas aeruginosa bacteriophage PP7 is used as a release criteria of 20 nm retentive membranes. Bacteriophage PP7 is an accepted standard model virus for small viruses such as the parvovirus.(1) (2) Ideally suitable for the rapid release of membranes, bacteriophages PP7 is fast growing and can reach high titer. Bacteriophage challenge testing is performed using a buffer (low salt buffer, pH 7.2) and buffered IVIG (1 g/L in low salt buffer, pH 7.2) at an end point of 75% blocking. This low salt buffer at pH 7.2 has been chosen so as to exclude the possibility of interactions between protein components with the virus and the membrane. Filtering until an end point of 75% flow decay has been reached represents testing that is commonly used during manufacturing and validation.

1.3.2 Product Release Testing

Two test methods are used for the release testing of devices and continuously assure the quality of Virosart® HF virus filters.

**Water Flow Rate Test**
Water permeability is an important parameter as protein throughput correlate to water flow rate. By testing the water flow rate of the final filter device, we can ensure reproducible, consistent and fast processing in the manufacturing process. The water flow rate of each individual Virosart® HF filter module is tested at 2.0 bar | 30 psi operating pressure.

**Integrity Test (IT)**
A water-based diffusion test is used to demonstrate the integrity of every final filter device. This non-destructive test ensures that only integral filters are released from production. Each individual Virosart® HF filter is tested for integrity (except non IT tested lab modules). The test pressure for diffusion testing is 4.5 bar | 65.25 psi and the testing and stabilization time is 5 min.
2. Throughput

2.1 Filtration Basics

2.1.1 Dead End Filtration
Modern virus filtration is a classical dead-end-filtration process. Pressure is applied on the feed stream side of the filter. The driving force for the filtration is the pressure difference across the membrane between feed and filtrate side.

2.1.2 Process Parameters
The course of a filtration can be described by different process parameters.

- **Differential Pressure:**
  DeltaP \([\Delta p]\) is a process value that is defined as the difference between pressure on the feed \([p_{\text{feed}}]\) and filtrate side \([p_{\text{filtrate}}]\). The differential pressure is usually controlled by the feed pressure as filtrate pressure is normally 0 bar | 0 psi.

  \[
  \Delta p = [p_{\text{feed}}] - [p_{\text{filtrate}}] = [\text{bar}; \text{psi}]
  \]

- **Flow Rate:**
  Flow rate \([J]\) is a process value that is defined as the filtered volume \([V]\) per time \([t]\).

  \[
  J = \frac{V}{t} = \left[ \frac{\text{mL}}{\text{h}; \text{min}} \right]
  \]
  Often, the flow rate \([J]\) is normalized to the filter area \([A_{\text{Membrane}}]\).

  \[
  J_{\text{Norm}} = \frac{J}{A_{\text{Membrane}}} = \left[ \frac{\text{L}}{\text{m}^2 \text{h}} \right]
  \]

- **Permeability:**
  The permeability \([P]\) is a key process parameter that defines the filter performance and directly affects batch production time. The permeability is represented by the flow rate \([J]\) over the membrane area \([A_{\text{Membrane}}]\) during a given time period. The permeability normally decreases with increasing filtration time due to the fouling of the filter by larger particles such as aggregates.

  \[
  P = \frac{J}{A_{\text{Membrane}}} \cdot \Delta p = \left[ \frac{\text{L}}{\text{m}^2 \text{h} \text{bar}} \right]
  \]

- **Product Throughput:**
  Product throughput \([V/A]\) describes the filtered volume \([V]\) per membrane area \([A_{\text{Membrane}}]\).

  \[
  \frac{V}{A} = \left[ \frac{\text{L}}{\text{m}^2} \right]
  \]

- **Product Mass Throughput:**
  The mass throughput \([m/A]\) defines the mass of product \([m]\) per membrane area \([A_{\text{Membrane}}]\).

  \[
  \frac{m}{A} = \left[ \frac{\text{kg}}{\text{m}^2} \right]
  \]

- **Flow Decay:**
  The flow decay \([J/J_{\text{Buffer}}]\) is defined as decay in product flow with respect to the initial buffer flow \([J_{\text{Buffer}}]\) at a respective time point.

  \[
  \frac{J}{J_{\text{Buffer}}} = \frac{J}{J_{\text{Buffer}}} = [\%]
  \]

2.1.3 Process Steps
Typically a virus filtration step includes following process steps:

1. Installation
2. Wetting for Pre-use IT
3. Wetting for Operations
4. Equilibration
5. Filtration
6. Post-Flush
7. Wetting for Post-use IT
8. Post-use IT

![Figure 2: Process steps during virus filtration](image)

- **1. Installation:**
  The equipment and the filter are to be installed and all sensors are to be connected.

- **2. Wetting for Pre-use IT:**
  In order to perform a water based diffusion test, the entire filter membrane area needs to be fully wetted with water for injection (WFI).

  **2.1 Pre-use IT:**
  An IT Test is performed to prove the integrity of the filter. A pre-use IT test is not required from a regulatory perspective, however a pre-use IT is strongly advised for risk mitigation purpose.

- **3. Wetting for Operation:**
  This ensures that the filter is particle-free and completely wetted so that the entire filter area is used during filtration.

- **4. Equilibration:**
  Prior to the product filtration, the filter and the equipment is equilibrated with buffer.
2.2 Filtration of mAbs

The Virosart® HF filter is specially developed for the filtration of mAbs and recombinant proteins. The virus filtration unit operation is typically located towards the end of the purification process. At this stage, the purity of the biopharmaceutical product is at its highest and virus filter fouling due to contaminants (DNA, HCP, aggregates and lipoproteins) is low. However, filterability can highly depend on the individual product molecule (size, pI, hydrophobicity) and its impurity profile (aggregates, fragments, HCPs, DNA).

Factors such as buffer composition, pH value, conductivity, operating pressure are known to potentially impact product throughput and productivity. In this study, the filtration performance for a variety of different representative mAbs is summarized to illustrate the range of typical product throughputs.

Materials and Methods

Virosart® HF lab modules (1.7 cm² or 5.0 cm²) were challenged with different mAb feed streams. In total, 10 different antibody solutions ranging in concentrations from 3 to 30 g/L were filtered at neutral pH value. The filtrations were performed at constant pressure of 2.0 bar | 30 psi using a 0.1 μm PES pre-filter (Sartopore® 2 XLM 4.5 cm²). In order to compare all filtration runs, the total product mass throughput was compared after 3 hours of filtration time. If the filtration was stopped before 3 hours of processing, the filtration was extrapolated using Vₘₐₓ up to a filtration time of 3 hours. This allowed a comparison to be made between the feed streams. The following formula describing Vₘₐₓ was applied:

\[
\frac{t}{V/A} = \frac{1}{V/A_{Max}} \cdot t + \frac{1}{J_0}
\]

with:
- \(t\) Time [h]
- \(V/A\) Product throughput [L/m²] filtered
- \(V/A_{Max}\) Maximum product throughput [L/m²]
- \(J_0\) Initial flow rate [L/m²h]

2.1.4 Process Control

Set up

Figure 3 describes a virus filtration set-up for commercial processing. Typically three solutions are needed (WFI, buffer, feed), as well as 2 types of sensors (flow, pressure), a peristaltic pump and valves.

Figure 3: Set-up for a typical virus filtration unit operation

Mode of Filtration

There are two ways to operate a virus filter:

1. Constant pressure: The filtration is operated at a constant pressure of 2.0 to 3.0 bar | 30.0 to 43.5 psi. The mode of operation most virus filtration steps are run at constant pressure. The pressure may be generated by either a compressed air source or pump.

2. Constant flow rate: The filtration is operated with a constant flow rate. The flow is normally controlled at a Δp of 1.0 bar | 14.5 psi at the beginning of the filtration. After reaching a certain pressure increase during the filtration, the flow rate is lowered to maintain the pressure.

5. Filtration:

In this step the product is filtered through the virus filter. The filtration can be operated under constant pressure or constant flow conditions.

6. Post Flush:

A post-use buffer flush is recommended to achieve maximum product yield.

7. Flushing for Post-use IT:

Prior to the post-use IT the membrane must be wetted with WFI.

8. Post-use IT:

An IT test is performed to prove the integrity of the virus filter. A post-use IT is mandatory from a regulatory perspective for the release of a batch.
During membrane release testing, bacteriophage PP7 retention is measured at 75% blocking. Also the time when 75% blocking is reached is documented. As the bacteriophage PP7 spike is not blocking the Virosart® HF membrane, these data can also be taken to compare consistent protein throughput of Virosart® HF. 42 lab modules from 8 different lots were challenged with highly blocking IVIG solution at a concentration of 1 g/L in 20 mM KPi buffer pH 7.2. The IVIG throughput was normalized to reference modules based on inhomogeneous IVIG feed stream from different batches (figure 7).

Results and Discussion
Inter- and intra-lot consistency of Virosart® HF performance is confirmed.

Consistent mAb throughput is shown for both membrane lots of Virosart® HF lab modules as shown in figure 5. Throughput varied minimally by 5% from 413 to 463 L/m² demonstrating consistent inter- and intra-membrane lot performance.

The data shown in figure 6 and figure 7 are representative for Virosart® HF product release testing. Consistent buffer permeability and protein throughput is shown for the Virosart® HF lab modules with minimal variation (less than ± 10%) within the given specifications.

2.3 Consistent Filter Throughput
Biopharmaceutical manufacturers expect consistent and reproducible throughputs from virus filters. During the development of the Virosart® HF and during routine production Sartorius Stedim Biotech ensures the highest quality standards by implementing and conducting comprehensive release tests as described in chapter 1.3.

Materials and Methods
In the following experiment, consistent throughput was confirmed by evaluating the performance of an antibody feed stream (mAb, IVIG) as well as buffer for inter- and intra-lot consistency of Virosart® HF virus filters. All filtration runs were performed at constant pressure of 2.0 bar | 30 psi.

To show consistent mAb throughput, Virosart® HF lab modules (1.7 cm²) from three different filter lots were challenged with a representative mAb solution of 5 g/L in 20 mM Tris HCL, pH 7 with 150 mM NaCl. The runs have been performed in duplicate, as shown in figure 5.

In addition, 96 filters from 8 different lots of filter modules were tested to prove inter- and intra-lot filter consistency for buffer permeability (figure 6). Virosart® HF lab modules with a filtration area of 5.0 cm² were used for the runs. To facilitate comparison, buffer permeability results were normalized to a temperature of 25°C | 77°F. 20 mM KPi at pH 7.2 was used as a buffer.
The protein concentration of the 2nd fraction (3 mL) was determined using a photometer at a wavelength of 280 nm (figure 8). The filtration was performed at 2.0 bar | 30 psi operating pressure.

**Results and Discussion**

Protein transmission is high throughout the entire IVIG filtration process. Figure 8 shows that the initial protein transmission in both runs exceeded 99%.

2.5 Scalability

Virosart® HF filter modules are available in 5 different sizes. These range from lab modules (1.7 and 5.0 cm²) used for scale-down work and GLP virus validation studies, mid-scale modules for pilot runs (200 cm² and 0.2 m²) to process modules (0.8 and 2.4 m²) used for commercial processing. From a process development perspective, scalability is a key factor to successfully transfer processes to large scale.

**Materials and Methods**

A set of experiments has been performed to demonstrate the scalability of flow rate and protein throughput across the size range of Virosart® HF filters. All runs were performed at 2.0 bar | 30 psi operating pressure.

Water flow rates for Virosart® HF filter family (device sizes of 1.7 cm², 5.0 cm², 200 cm², 0.2 cm², 0.8 m² and 2.4 m²) have been tested using 3 different lots of filter modules with 10 filters from each lot. To facilitate the comparison of different runs, water flow rates were normalized to a temperature of 25°C | 77°F (figure 9).

Three different 5.0 cm² Virosart® HF lab modules and one 0.8 m² process module were challenged with a 2 g/L buffered IVIG model solution at 2.0 bar | 30 psi constant pressure until 95% flow decay was achieved. The pre-treatment of lab and process modules was identical (figure 10).
2.6 Post-Flushing Volume
A post-use flush is often performed during the virus filtration step in commercial production in order to recover protein and increase yield. The Virosart® HF filter family was developed to have low hold up volumes and thereby reduce product dilution as well as reduced buffer consumption and costs. The goal of this experiment was to determine the flushing volume required to reach a 99% recovery of the target protein.

Materials and Methods
A Virosart® HF process module with 0.8 m² surface area was used to determine the flushing volume required to reach 99% product recovery. Buffered IVIG solution with a concentration of 2 g/L was processed through the filter at 2.0 bar | 30 psi until a 40% flow decay was reached. A slightly higher concentration was used in this experiment to reach faster the level of flow decay. The feed stream was then changed from the IVIG solution to a buffer. An in-line UV-detector in the filtrate stream was used to determine the protein concentration.

Results and Discussion
Buffer savings are possible with Virosart® HF due to minimal post-flushing volumes. Figure 11 shows that the flushing volume required in order to reach 99% product recovery is 3 L/m².

2.7 Hold-up Volume
It is important to know filter wet and hold-up volumes in order to optimize production processes. The Virosart® HF modules are designed and developed to have minimal wet and hold-up volumes.
3. Process Optimization

3.1 Fouling Behavior of Virus Filters

Virus filtration performance is often a function of feed stream properties such as buffer composition, pH, conductivity, process pressure, impurity and aggregate levels, protein concentration and protein characteristics. These can lead to different fouling behaviors being observed during filtration operations.

The main reason for flow decay in virus filtration is fouling caused by fouling species that are present in the feed stream such as process impurities and protein aggregates. Aggregates may have a similar size to the pores of the virus filter and become retained by the membrane.

Materials and Methods

The wet volume and the hold-up volume was determined for every Virosart® HF module in the product family.

- **1. Wet Volume:**
  Defined as volume of water required to completely fill the module (upstream and downstream side of the membrane). In order to determine the wet volume the difference in weight between empty and filled capsules are determined for each module (figure 12, top).

- **2. Hold-up Volume:**
  Defined as the volume left in the module once emptied with pressurized air at 4.5 bar | 65.2 psi inlet pressure. Here, only the downstream side of the filter contains liquid as indicated in figure 12, bottom. After emptying, the module was weighed to determine the hold-up volume.

![Figure 12: Wet volume (top) and hold-up volume (bottom) of the Virosart HF™](image)

### Results and Discussion

Minimal need of hold and flushing volumes for the entire family of Virosart® HF. The results are presented in table 1 for each size.

![Figure 13: Virus filter fouling due to aggregates being present in the feedstream](image)

<table>
<thead>
<tr>
<th>Area</th>
<th>Wet volume [mL]</th>
<th>Hold-up volume [mL]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lab module</td>
<td>5.0 cm²</td>
<td>2</td>
</tr>
<tr>
<td>Mid-scale module</td>
<td>200 cm²</td>
<td>50</td>
</tr>
<tr>
<td>0.2 m²</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>Process module</td>
<td>0.8 m²</td>
<td>650</td>
</tr>
<tr>
<td>2.4 m²</td>
<td>575</td>
<td></td>
</tr>
</tbody>
</table>

Table 1: Wet and hold-up volume for Virosart® HF filter family

### Solutions for Virus Filter Fouling

- Adsorptive pre-filtration (chapter 3.2) to remove process impurities and aggregates.
- Application of virus filtration unit operation further downstream, if possible, where impurities and aggregate levels are lower.

A change of feed stream conditions can also have a positive impact on the fouling behavior:

- Dilution (chapter 3.3)
- Conductivity (chapter 3.4)
- pH (chapter 3.4)
- Buffer
3.2 Adsorptive Pre-Filtration with Virosart® Max

Virosart® Max is a pre-filter which is designed to significantly increases the performance of downstream virus filters. The Virosart® Max pre-filter utilizes mostly its adsorptive capacity, together with size exclusion, to retain typical virus filter foulants.

By removing these virus filter foulants, process robustness can be significantly increased. The species that typically are responsible for fouling virus filters are product aggregates and smaller hydrophobic species. Using the patented technology of Virosart® Max (DE 10 2011 105 525 B4), aggregates and hydrophobic species are bound very efficiently through hydrophobic interactions of the polyamide membrane material, independent of process conditions such as pH and conductivity.

Since the Virosart® Max removes most of the hydrophobic species by adsorption, the surface area of pre-filter needed is important to determine. Two different studies have been performed to test the impact of adsorptive pre-filtration and to optimize the ratio of pre-filter to final-filter area.

3.2.1 Use of Adsorptive Pre-Filters

In this study, the effect of Virosart® Max on the overall product throughput using Virosart® HF was tested.

Materials and Methods

The overall product throughput of Virosart® HF lab modules was tested with and without in-line adsorptive pre-filtration with Virosart® Max. Different mAb solutions ranging in concentration from 3 g/L up to 30 g/L were filtered with and without the use of Virosart® Max. All filtration runs were run at 2.0 bar | 30 psi constant pressure. The filtration runs were extrapolated up to 3 hours filtration time using V_max.

Results and Discussion

By the use of Virosart® Max as an adsorptive inline pre-filter (figure 14), mass throughput may be increased significantly for most of the feed streams tested. The overall product throughput can be improved by 10% up to 50% specifically for feed streams containing a high amount of foulants such as aggregates. The use of an adsorptive inline pre-filter before the virus filter is recommended to guarantee process robustness and to improve process economics.

![Figure 14: Impact of inline pre-filtration on the overall throughput of Virosart® HF](image)

3.2.1 Optimization: Pre-filter to Final-filter Ratio

Further improvement of process economics can be achieved by optimizing the ratio of adsorptive pre-filter to final-filter area. Since the Virosart® Max removes most of the hydrophobic species by adsorption, the surface area of pre-filter needed is important to determine. By increasing adsorptive pre-filter area, more foulants that tend to block the virus filter, e.g. aggregates can be removed.

Materials and Methods

In this study, different pre-filter to final filter ratios were tested in order to achieve optimal virus filter throughput for two specific feed streams (IVIG, mAb). Filtration was carried out at a constant pressure of 2.0 bar | 30 psi. In the first experiment a high fouling IVIG feed stream was filtered with different adsorptive pre-filter ratios of 0:1, 1:1 and 4:1 (figure 15). In the second experiment the mAb feed stream was filtered with a 0:1, 3:1 and 6:1 pre-filter final-filter ratios (figure 16).

Results and Discussion

The throughput of Virosart® HF increases with increased adsorptive pre-filtration area of Virosart® Max. As shown in figure 15, using the virus filter alone resulted in a continuously decreasing flow rate as the virus filter is challenged with a constant concentration of foulants. By increasing the adsorptive pre-filtration area, the overall product throughput over the virus filter can be extended significantly. Here specifically the adsorptive capacity increases thus extending the loading phase. During the loading phase the capacity of the adsorptive pre-filter is not fully used and no foulants can breakthrough. During the further course of filtration, flow decay sets is a consequence of overloading the pre-filter.

Product throughput can be increased significantly by increasing the adsorptive pre-filter area as shown in and figure 16 for the mAb feed stream used. The capacity can be doubled by using a pre-filter to final-filter ratio of 3:1 with an overall capacity of 1.5 kg/m² after 3 hours of filtration when compared to the case without adsorptive pre-filter. The highest product throughput of 2.0 kg/m² can be reached by using a 6:1 pre-filter to final-filter ratio.
Results and Discussion
Dilution of feed stream can increase product throughput significantly. As seen in figure 17, the overall product throughput over the virus filter can be improved by dilution for challenging feed streams. The product throughput can be increased from 2 kg/m² up to approx. 6.5 kg/m² after 3 hours of filtration by applying a two-step dilution.

3.4 pH and Conductivity
Adapting the pH and conductivity of the feed stream can influence molecule folding as well as protein-protein interaction and can therefore have an impact on product throughput performance during virus filtration.

Materials and Methods
The effect of pH-shift and conductivity shift on the product throughput of Virosart® HF lab modules was tested. pH value and conductivity of a challenging-to-filter mAb feed stream were adjusted. The pH was varied around neutral pH (7, 8, 8.5) and different conductivities (100, 200, 300 mM) were chosen (figure 18).

Results and Discussion
Adapting pH and conductivity can positively impact virus filter throughput.

The optimal feed stream conditions for the mAb appears to be at neutral pH and a conductivity of 100 mM showing 6 times the product throughput in comparison to the other conditions tested as shown in figure 18.
4. Virus Clearance

4.1 Introduction

4.1.1 Definition of LRV
Retention during virus clearance unit operations is calculated as a $\log_{10}$ reduction value (LRV), which is the logarithmic ratio of the virus titer in the feed $[C_{\text{Feed}}]$ to the virus titer in the filtrate $[C_{\text{Filtrate}}]$:

$$\text{LRV} = \log_{10} \frac{C_{\text{Feed}}}{C_{\text{Filtrate}}}$$

Typical reduction values given by filter manufactures for virus filters are:

- $\geq 4$ LRV for small non-enveloped viruses
- $\geq 6$ LRV for large enveloped viruses

4.1.2 Model Virus
Validation studies with viruses, so called “spiking studies”, are generally performed in contract laboratories that have the capabilities to prepare, realize and document spiking studies based on scaledown models from customer-specific manufacturing processes. An initial study is normally required prior to the manufacture of clinical Phase I material and is aimed validating effective and adequate clearance of viruses. A subsequent and more comprehensive study is then conducted prior to clinical phase III to provide evidence of the effective and adequate clearance of relevant and known viruses along with the removal of a range of novel and unpredictable viruses. They are differentiated as follows: (3)

- Relevant virus: The identified virus, or of the same species as the virus that is known, or likely to contaminate the cell substrate or any other reagents or materials used in the production process.
- Specific model viruses: Viruses that are physically and chemically similar to relevant viruses like same genus or family.
- Non-specific model viruses: Viruses that represent wide range of physicochemical properties in order to test the ability of the system to eliminate virus in general.

3.5 Decision Tree for Virus Filter Throughput Optimization

The figure 19 summarizes the chapter optimization based on a dision tree for virus filter optimization.

Figure 18: Variation of pH and conductivity impacting the virus filter throughput

Figure 19: Decision tree for virus filter throughput optimization

3.5 Decision Tree for Virus Filter Throughput Optimization

The figure 19 summarizes the chapter optimization based on a dision tree for virus filter optimization.
4.2 Virus Retention

4.2.1 MuLV Retention
Murine Leukemia Virus (MuLV) is a standard model virus used to validate the clearance of large enveloped viruses in products derived from cell lines. Typically the virus is used in spiking studies performed prior to entrance into phase I and phase III clinical trials.

Materials and Methods
MuLV retention results were summarized from different individual experiments. The runs were performed at different contract testing organizations with different feed steams and experimental set-ups. All studies were performed with duplicate runs at an operating pressure of 2.0 bar | 30 psi. Therefore specific conditions such as product concentration, buffer composition, product throughput, fractions taken, MuLV spike level etc. are process specific (figure 20).

Results and Discussion
High retention of MuLV with no virus breakthrough detected for all runs of Virosart® HF.

MuLV results from different experiments were collected in figure 20. Filtration runs were performed at different contract testing organizations with different feed steams most at neutral pH with typical operating pressure of 2.0 bar | 30 psi. In all trials, no virus breakthrough was detected. The distribution results from different feed titer used in the experiments.

4.2.2 PPV Retention
Porcine Parvo Virus (PPV) is a standard model virus used to evaluate the clearance of small-non enveloped viruses in products derived from cell lines. (5)

Materials and Methods
The Virosart® HF was tested with a feed stream comprising PPV spiked IVIG solution at a concentration of 1 g/L in 20 mM KPI buffer, pH 7.2. Two spiked runs were performed with different virus titer in the feed with the first containing 5 × 10^5 pfu/mL and the second containing 5 × 10^6 pfu/mL. The LRV results present fractions taken up to 25% and up to 70% flow decay. The log reduction value was also determined in the post-wash fraction and the overall filtrate and wash pool. The studies were performed by an external contract laboratory.

Results and Discussion
LRVs of 6 and greater are shown in figure 21 for all fractions taken for both runs. The LRV for PPV was also high in the post-wash fraction. The filter achieved high and reproducible LRVs for PPV regardless of the extent of fouling.

Further details regarding model viruses can be found in the virus information guide (10). Data showing no virus breakthrough are indicated in the figures with filled points and data with virus breakthrough are unfilled respectively.

Table 2: Viruses and bacteriophages used for following studies (2) (8)

<table>
<thead>
<tr>
<th>Virus</th>
<th>Description</th>
<th>Enveloped</th>
<th>Genome Type</th>
<th>Size [nm]</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPV</td>
<td>Model virus for small non-enveloped virus</td>
<td>No</td>
<td>ssDNA</td>
<td>18 – 24</td>
</tr>
<tr>
<td>MVM</td>
<td>Model virus for small non-enveloped virus</td>
<td>No</td>
<td>ssDNA</td>
<td>18 – 26</td>
</tr>
<tr>
<td>MuLV</td>
<td>Model virus for large enveloped viruses</td>
<td>Yes</td>
<td>ssRNA</td>
<td>80 – 110</td>
</tr>
<tr>
<td>PP7</td>
<td>Proven bacteriophage model for parvoviruses (9)</td>
<td>--</td>
<td>ssRNA</td>
<td>26</td>
</tr>
</tbody>
</table>

Figure 20: Summary of MuLV retention from different studies. LRV distribution is resulting from the different feed virus titer

Figure 21: Retention of PPV at 25% and 70% blockage as well as post wash
### Materials and Methods

**Virosart® HF lab modules were challenged with PP7 spiked model feed solutions (challenge level > 5 × 10^7 pfu/mL). In total, five different feed solutions were tested at neutral pH. Retention data in buffer (20 mM KPi buffer, pH 7.2) and IVIG (1 g/L IVIG, 20 mM KPi buffer, pH 7.2). For mAb containing feed streams, mAb concentrations ranged from 4 – 12 g/L. All filtrations were performed at constant operating pressure of 2.0 bar | 30 psi.**

### Results and Discussion

Virosart® HF shows robust and high PP7 clearance for all tested model solutions with LRVs of above 6.

#### Materials and Methods

Product release data from randomly chosen virus filter membrane lots of Virosart® HF (5.0 cm²) were collected. The filtrations were performed in constant pressure mode at 2.0 bar | 30 psi.

#### Results and Discussion

Robust intra- and inter-lot PP7 retention consistency was demonstrated for Virosart® HF. Retention exceeded 6 LRVs using buffer as well as under 75% flow decay.

---

### 4.3 Robust Retention

#### 4.3.1 Retention in Different Feed Streams

Feed streams to be processed by virus filtration are highly individual and can differ significantly from process to process. Feed stream can vary in parameters such as the molecule of interest (size, pI, hydrophobicity), impurity profile (aggregates, fragments, HCPs, DNA) and the formulation (buffer type, pH, conductivity, additives). Therefore, Virosart® HF was tested with respect to retention capabilities of PP7 in different model feed streams: Buffer, IVIG, and three mAb solutions.

---

### 4.2.3 MVM Retention

Minute Virus of Mice (MVM) is a standard model virus used to evaluate the clearance of small-non enveloped viruses in products derived from cell lines. (5)

#### Material and Methods

Different studies were performed with Virosart® HF lab modules showing MVM retention in duplicate runs.

The runs were performed in different contract testing organizations with different feed steams and experimental set-ups. Therefore specific conditions such as product concentration, buffer composition product throughput, fractions taken, MVM spike level etc. are process specific. All runs were performed at constant operating pressure of 2.0 bar | 30 psi.

#### Results and Discussion

Robust intra- and inter-lot PP7 retention consistency was demonstrated for Virosart® HF. Retention exceeded 6 LRVs using buffer as well as under 75% flow decay.

---

### 4.3.2 Virus Filter Intra- and Inter-Lot Retention Consistency

Understanding the intra- as well as inter-lot consistency of virus filters such as Virosart® HF with respect to virus retention is of especially high importance during validation studies as well as during clinical and commercial processing.

#### Materials and Methods

Product release data from randomly chosen virus filter membrane lots of Virosart® HF (5.0 cm²) were collected. The filtrations were performed in constant pressure mode at 2.0 bar | 30 psi.

#### Results and Discussion

Robust intra- and inter-lot PP7 retention consistency was demonstrated for Virosart® HF. Retention exceeded 6 LRVs using buffer as well as under 75% flow decay.
Results and Discussion

The scalability of PP7 retention has been demonstrated across the entire product family of Virosart® HF filters from lab (1.7 cm²) up to process scale (2.4 m²).

4.3.3 Scalability of Retention

Virosart® HF lab modules are typically used for R&D, process scale-down work and virus validation studies. However, in commercial processing larger devices with larger filtration areas are used. It is, therefore, necessary to ensure robust and scalable retention across the entire size range of Virosart® HF filter family.

Materials and Methods

The scalability of PP7 retention was studied for the entire product family of Virosart® HF from lab (1.7 & 5.0 cm²) through mid-scale (200 cm² & 0.2 m²) to process scale (0.8 & 2.4 m²). All filtrations were performed at a constant pressure of 2.0 bar | 30 psi. All modules were spiked with PP7 at a minimum concentration of 1.0 × 10⁸ PFU/mL. PP7 was spiked into 20 mM KPI buffer pH 7.2 (figure 26) or into 1 g/L IVIG in KPI buffer (figure 27).
4.4.1 Flow Decay
Different virus filters show increased level of virus breakthrough at increasing level of flow decay of 75% or higher.

Material and Method
22 lab modules (1.7 cm²) from different production lots were tested for their PP7 retention capabilities (challenge level > 10⁷ pfu/mL) at increasing level of flow decay. Three fractions were taken, namely at 25%, 75% and 90% flow decay. The filtration was performed with IVIG (1 g/L, 20 mM, pH 7.2) at a constant pressure of 2.0 bar | 30 psi.

Results and Discussion
Under the condition tested, no significant impact of the different operating pressures on virus retention capabilities was observed in buffer and at 75% flow decay. LRVs of approximately 6 for low, moderate and high pressures were demonstrated, as shown in figure 29. Robust LRVs of 5 or greater were demonstrated at 75% flow decay (figure 30).

4.4.2 Different Operating Pressures
Virosart® HF virus filters are typically validated at 2.0 bar | 30 psi operating pressure to meet standard processing requirements. The filters are released for operation up to 5.0 bar | 72.5 psi operating pressure. Experiments have been performed to show that operating at low or high operating pressures does not affect the retention characteristics of Virosart® HF. The experiments have been performed with buffer only and with IVIG at 75% flow decay.

Materials and Methods
Retention capabilities were determined at low (0.1 bar | 1.45 psi), normal operating pressure (1.0 bar | 14.5 psi) and high (5.0 bar | 72.52 psi) operating pressures (figure 29). 12 lab modules (5.0 cm²) were tested for retention of the PP7 bacteriophage. PP7 (challenge level > 10⁷ pfu/mL) was spiked in 20 mM KPI buffer, pH 7.2. A pooled fraction was taken after 5.0 mL (0.1 bar | 1.45 psi) and after 50 mL (1.0 bar | 14.50 psi and 5.0 bar | 72.52 psi) of filtration.

Experiments were performed at 3 different operating pressures of 1.0 bar | 14.5 psi, 3.0 bar | 43.5 psi, 4.0 bar | 58 psi (figure 30). 20 lab modules (5.0 cm²) from one production lot were tested for retention with a buffered IVIG (1g/L) solution spiked with PP7 (challenge level > 10⁷ pfu/mL). A pooled fraction was taken after 75% flow decay.

Results and Discussion
Under the condition tested, no significant impact of the different operating pressures on virus retention capabilities was observed in buffer and at 75% flow decay. LRVs of approximately 6 for low, moderate and high pressures were demonstrated, as shown in figure 29. Robust LRVs of 5 or greater were demonstrated at 75% flow decay (figure 30).
4.4.3 Pressure Release
During commercial processing pressure release occurs on a regular basis e.g. if the processing media is changed. Data has shown that virus breakthrough is more likely to occur with some virus filters when the pressure is released. For this reason, a pressure release cycle is often included in spiking studies to show the retentive capabilities of the virus filter under this processing condition.

Materials and Methods
Five lab modules (5.0 cm²) from one production lot were tested for their PP7 retention capabilities. PP7 (challenge level > 1 × 10⁷ pfu/mL) were spiked in 20 mM KPi buffer, pH 7.2. A 5-minute pressure release was performed and four pool fractions were taken. These fractions were taken after 30, 40, 140 and 150 L/m² of filtration. The filtration was performed at 2.0 bar | 30 psi operating pressure.

Results and Discussion
High LRVs of above 5.5 are shown in figure 31 for all fractions, even after pressure release. Further studies were performed with 5 g/L mAb model solution, which confirmed these results. (6)

![Figure 31: Impact of pressure release on PP7 retention of Virosart® HF](image)

4.4.4 Pressure Pulsation
Compressed air is typically used as a pressure source to run a virus filter in stainless steel, but pumps can also be used. In single-use manufacturing peristaltic pumps are commonly used when performing virus filtrations with single-use assemblies in order to operate at low bag pressure. Peristaltic pumps can create pressure pulsation which could potentially impact retention performance of the virus filter. Therefore, the retention performance of Virosart® HF filters was assessed using a peristaltic pump as the fluid delivering force.

Materials and Methods
Two lab modules (5.0 cm²) from one production lot were tested for their ability to retain PP7 at a challenge level of 1 × 10⁷ pfu/mL in 20 mM KPi buffer, pH 7.2. A Watson Marlow 520 peristaltic pump was used with pulsation of ± 0.3 bar | ± 4.4 psi at medium operating pressure of 1.4 – 1.5 bar | 20.3 – 21.8 psi. This was deemed a worst-case scenario for pump pulsation. Fractions were taken after 30, 100, 200 and 300 L/m² of filtration.

Results and Discussion
No impact of pressure pulsation on the retention for Virosart® HF observed.

No virus breakthrough was detected and overall LRVs were above 6.5. However, we recommend pumps with lower pulsation (e.g. 4 piston diaphragm pump) in commercial processing due to the shear sensitivity of most proteins.

![Figure 32: The impact of pressure pulsation tested on PP7 retention](image)

4.4.5 High Virus Load
Some virus retentive filters on the market show the tendency for increased virus breakthrough with increasing virus load on the virus filter. In this experiment the impact of PP7 virus load on the retention of Virosart® HF was evaluated.

Materials and Methods
Six Virosart® HF lab modules (1.7 cm²) from one lot were used in these experiments. The filters were challenged with 20 mM KPi buffer, pH 7.2 spiked with PP7 at a high challenge level of 2.5 × 10⁹ Pfu/mL. In total, four pool fractions were taken after 60, 350, 900 and 1000 L/m² of filtration. The fractions taken are representative for different overall virus loads 1.5 × 10¹³, 9.4 × 10¹², 2.4 × 10¹⁴, 2.6 × 10¹⁴ pfu/m². The filtration runs were performed at a constant pressure of 2.0 bar | 30 psi.
Results and Discussion

Robust virus retention at increased virus load observed with Virosart® HF. No impact of virus load on PP7 retention of Virosart® HF was observed under the conditions tested even with a high PP7 load of $10^{14}$ pfu/m² as shown in figure 33.

4.4.6 Low pH & High Salt Concentration

The feed streams processed during the virus retentive step typically have neutral pH values and low salt concentration. Feed streams at low pH values and high salt concentrations are rare. However, some virus filters have shown increased virus breakthrough under these conditions. Analogous to the high virus load experiments at neutral pH (see section 4.4.5), the impact of low pH and high salt concentration was evaluated at similarly challenging high virus loads.

Materials and Methods

Four Virosart® HF lab modules (1.7 cm²) were tested for their retention capabilities under two different conditions. The filters were challenged with acetate buffer at pH 4.3 with a high salt concentration (200 mM). PP7 bacteriophage was spiked at a challenge level of $1 \times 10^6$ pfu/mL. Different fractions were taken as the virus loading level increased from $1.6 \times 10^{13}$ to $4.7 \times 10^{14}$ pfu/m². These are representative for throughputs of 60, 350, 950 and 1200 L/m². The filtration runs were performed at a constant pressure of 2.0 bar | 30 psi.

Results and Discussion

No impact of worst-case conditions on retention was observed. The retention at low pH and high salt concentration, high product throughput and high PP7 challenge level was above 6 LRV.

4.4.7 Detergents

Some feed streams may contain surface active ingredients such as detergents. In this study, the effects of detergents on the retention capabilities of Virosart® HF was evaluated using two representative solutions containing Tween 80 or SDS.

Materials and Methods

Virosart® HF lab modules (1.7 cm²) from one production lot were tested for their ability to retain PP7 at a challenge level of greater than $1 \times 10^8$ pfu/mL in two model solutions containing detergents: 0.1% Tween 80 in 20 mM KPI pH 7.2 and 0.1% SDS in 20 mM TRIS pH 10.2. Four fractions were taken, which included a pressure release of 20 minutes. Each solution was tested with four modules each. The filtration runs were performed at 2.0 bar | 30 psi operating pressure.

Results and Discussion

No impact of detergents on the retention of Virosart® HF could be detected. LRVs of more than 7 were observed even though the two model feeds contained either Tween 80 or SDS.
4.5 Simulation of Transportation Conditions

Testing was performed to simulate the transportation of filter modules from the location of their production to their location of use.

4.5.1 Drop-Test

A drop-test is part of the shipping validation performed in accordance to guideline ASTM 7386. During this test the final shipping box is dropped in a strictly defined way from a specified height (1 m | 3.3 ft).

Materials and Methods

12 gamma irradiated lab modules (5.0 cm²) from one production lot were tested for their ability to retain PP7 at a challenge level of $2.1 \times 10^8$ PFU/mL in 20 mM KPI buffer, pH 7.2 after they had been dropped from 1 m | 3.3 ft height. The filtration process was performed at a constant pressure of 2.0 bar | 30 psi. A pool fraction was taken after 100 L/m² of filtration volume.

Results and Discussion

No effect of the drop test on PP7 retention was observed. LRVs of greater than 5.5 were demonstrated for all filters tested (figure 36). However, it is not recommended to drop the boxes. (6)

4.5.2 Thermal Stress

The effect of temperatures lower than 0°C | 32°F, that may occur during the transportation and storage of Virosart® HF filters, was evaluated with respect to retention performance.

4.5.3 Mechanical Stress

Plastics show an increased brittleness at low temperatures which represents the worst case condition during mechanical stress tests. Therefore, the effect of mechanical stress conditions during transporting and storage on the retention performance of Virosart® HF filters was evaluated.

Materials and Methods

Four lab modules (5.0 cm²) from one production lot were stored at –18°C | –0.4°F for 22 hours followed by storage at room temperature for two hours. This process was repeated for 3 cycles (figure 38). PP7 retention (challenge level > $10^8$ PFU/mL) was then determined in 20 mM KPI buffer at pH 7.2. The filtration was performed at a constant pressure of 2.0 bar | 30 psi. A pool fraction was collected after 100 L/m² of filtration.

Results and Discussion

No effect of thermal stress conditions on PP7 retention was observed. Robust LRV of above 6 is shown. However, note that the shelf life is validated under the storage conditions described in the validation guide.
5. Integrity Test

5.1 Definition

Virus retentive filters such as Virosart® HF are integrity tested based on a diffusion test. A constant test pressure is applied on the upstream side of the wetted membrane (figure 41). A pressure drop is created on the upstream side as the air molecules are diffusion through the membrane towards the downstream site of the filter. The Sartocheck® is measuring the pressure drop on the upstream site. Integrity test is performed at one defined test pressure of 4.5 bar | 65 psi with the test criterion of a max. diffusion rate. The IT has passed when the measured diffusion rate does not exceed the limit value.

![Diagram of Integrity Test](image)

Figure 41: Schematic drawing of the Integrity Test based on diffusion. Applying test pressure to upstream side results in gradient from upstream side to downstream side, thus a net flux in the direction of filtration. This situation is relevant for integer devices, where the Bubble Point of the membrane has not been reached by the test pressure.

5.2 Reasons

An appropriate measurement method is required using non-destructive techniques that facilitates a statement with respect to filter integrity. In addition, integrity testing of virus retentive filters are necessary to

- fulfil regulatory requirements
- confirm integrity of the filter element prior to and after use
- detect system leaks in the filtration system
- prevent contamination events

The FDA “Guidelines on Sterile Drug Products Produced by Aseptic Processing”, state: “After a filtration process is properly validated for a given product, process and filter, it is important to assure that identical filter replacements (membrane or cartridge) used in production runs will perform in the same manner. Normally, integrity testing of the filter is performed after the filter unit is assembled and sterilized prior to use. More importantly, however, such testing should be conducted after the filter is used in order to detect any filter leaks or perforations that may have occurred during filtration.” (11)

Results and Discussion

No effect of mechanical stress condition on PP7 retention was observed. Robust LRV of above 5.9 is shown. However, note that the shelf life is validated under the storage conditions described in the validation guide.

![Graph of LRV (PP7, buffer)](image)

Figure 40: No effect of mechanical stress transport condition on PP7 retention

![Graph of Throughput (L/m²)](image)

N = 4
Further a correlation between bacteriophage PP7 retention of Virosart® HF Filters and a non-destructive integrity test has to be established in order to ensure filter reliability prior to using the filter.

5.3 Correlation of IT and PP7 Retention

A correlation is established between destructive bacteriophage PP7 retention and non-destructive integrity test for Virosart® HF. Therefore a positive and a negative correlation was performed during product validation to confirm the integrity test value.

• Positive correlation: IT passed and retention passed
• Negative correlation: IT not passed and retention not passed (performed with limiting filter samples)

Materials and Methods

Virosart® HF process modules (0.8 m²) from different production lots were tested for their retention capability of the bacteriophage PP7. The negative correlation was performed with limiting filter samples.

As described in figure 43 the filters were wetted in the flow through mode for > 20 minutes at an inlet pressure of 2.5 bar | 36 psi against an outlet pressure of 2.0 bar | 30 psi. After wetting, the modules were tested for integrity by a diffusion test at 4.5 bar | 65 psi. Next, the elements were then challenged with a minimum of 10⁷ PP7/mL in 20 mM potassium phosphate buffer (KPi), pH 7.2 at 2.0 bar | 30 psi. Fractions for LRV were collected after 10 liters of filtration. Finally, an integrity test based on diffusion was performed post PP7 retention test at 4.5 bar | 65 psi.

Results

Positive (grey) and negative correlation (yellow) confirm IT-limit of 20 mL/ min for Virosart® HF process modules (0.8 m²). The diffusion data presented in figure 44 was recorded post-use.

Figure 44: Correlation of PP7 retention and diffusion value for Virosart® HF process modules (0.8 m²)

6. Abbreviations

DNA Deoxyribonucleic acid
HCP Host Cell Protein
IVIG Intravenous immunoglobulin
IgG Immunogamma Globulin
IT Integrity tested
KPI Potassium Phosphate
LRV Log reduction value
mAb Monoclonal antibody
MuLV Murine Leukemia Virus
MVM Minute Virus of Mice
Pfu Plaque forming units
PES Polyethersulfone
SDS Sodium dodecyl sulfate
WFI Water for injection
7. References


(3) ICHQ5A; Viral Safety Evaluation of Biotechnology products derived from cell lines of human or animal origin; 1999

(4) Application Note: Impact of Pressure Release and Multiple Pressure Fluctuations on Virus Retention Performance of Virosart® HF Virus Retentive Filters (SPK4112-e)

(5) Mahmood Farshid, Ph.D.Div. Of Haematology OBRR | CBER | FDA

(6) Validation Guide Virosart® HF (SPK5801-e)

(7) Note for Guidance on Virus Validation Studies: The Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses, EMEA CPMP BWP, 268/95 1996


(10) Virus Information Guide; SPK5752-e16023

(11) Guidelines on Sterile Drug Products Produced by Aseptic Processing

8. Acknowledgements

The authors would like to thank Magnus Warnke, Swetlana Macht, Ralf Wittmeier and the bacteriophage lab team (Andreas Schwerdt, Pia Lehmann, Tabea Streil, Miriam Börger) from Sartorius for conducting the studies.